The Pilot &Feasibility Program is a key element in moving Tobacco Regulatory Science forward rapidly and efficiently at UNC-Chapel Hill. This Program is ideally suited to allow young investigators in particular to develop novel ideas and concepts prior to submitting for national funding. We anticipate that the pool of P&F applicants will predominantly be located on the UNC-CH campus. However, if warranted, we are prepared to consider P&F grant applications from our collaborators at Duke Medical School, NC State and other TCORS Centers that fit in with our theme of """"""""Impaired Innate Defense with Tobacco Exposure"""""""". We would note that we have had extensive experience with this type of program in the context of the Cystic Fibrosis Foundation Pilot &Feasibility Program which we have run over the past fifteen years. We developed an algorithm that we believe was successful in that endeavor which we would use for the TCORS P&F program. This will include the following: 1) An eariy (six months prior to submission date) and widely disseminated announcement (on the UNC Pulmonary Division, Cystic Fibrosis/Pulmonary Research and Treatment Center, COPD Center and Center for Environmental Medicine and Curriculum in Toxicology websites, e-mail networi<, and through oral disclosures at weekly meetings) of the availability of Pilot &Feasibility projects;2) a pre-review of one to two page outlines of Pilot &Feasibility Projects with the Director and Co-Director ofthe TCORS P&F Program;3) a review (including an NIH-type priority score) of the Pilot &Feasibility Programs by the Program Director, Co- Director, other Co-investigators and at least two members of the Advisory Committee who are experts in the area pertinent to the P&F and 4) the development of a database/tracking mechanism to follow in the outlying years the success of the P&F grant program in generating extramural funding. In the past, we have been particularty successful in the P&F Program in developing the science required for successful multi-investigator grant applications, including Program Projects. Further, this mechanism has been highly successful in generating successful KOS, K21, and ROI applications for junior faculty. Thus, we would plan to model the TCORS P&F Program award mechanism along similar lines.
| Keating, James E; Minges, John T; Randell, Scott H et al. (2018) Paper Spray Mass Spectrometry for High-Throughput Quantification of Nicotine and Cotinine. Anal Methods 10:46-50 |
| Reidel, Boris; Radicioni, Giorgia; Clapp, Phillip W et al. (2018) E-Cigarette Use Causes a Unique Innate Immune Response in the Lung, Involving Increased Neutrophilic Activation and Altered Mucin Secretion. Am J Respir Crit Care Med 197:492-501 |
| Ghosh, Arunava; Coakley, Raymond C; Mascenik, Teresa et al. (2018) Chronic E-Cigarette Exposure Alters the Human Bronchial Epithelial Proteome. Am J Respir Crit Care Med 198:67-76 |
| Rebuli, Meghan E; Speen, Adam M; Clapp, Phillip W et al. (2017) Novel applications for a noninvasive sampling method of the nasal mucosa. Am J Physiol Lung Cell Mol Physiol 312:L288-L296 |
| Esther Jr, Charles R; Hill, David B; Button, Brian et al. (2017) Sialic acid-to-urea ratio as a measure of airway surface hydration. Am J Physiol Lung Cell Mol Physiol 312:L398-L404 |
| Kesimer, Mehmet; Ford, Amina A; Ceppe, Agathe et al. (2017) Airway Mucin Concentration as a Marker of Chronic Bronchitis. N Engl J Med 377:911-922 |
| Davis, Eric S; Sassano, M Flori; Goodell, Henry et al. (2017) E-Liquid Autofluorescence can be used as a Marker of Vaping Deposition and Third-Hand Vape Exposure. Sci Rep 7:7459 |
| Clapp, Phillip W; Pawlak, Erica A; Lackey, Justin T et al. (2017) Flavored e-cigarette liquids and cinnamaldehyde impair respiratory innate immune cell function. Am J Physiol Lung Cell Mol Physiol 313:L278-L292 |
| Clapp, Phillip W; Jaspers, Ilona (2017) Electronic Cigarettes: Their Constituents and Potential Links to Asthma. Curr Allergy Asthma Rep 17:79 |
| Rowell, Temperance R; Reeber, Steven L; Lee, Shernita L et al. (2017) Flavored e-cigarette liquids reduce proliferation and viability in the CALU3 airway epithelial cell line. Am J Physiol Lung Cell Mol Physiol 313:L52-L66 |
Showing the most recent 10 out of 20 publications
